Humana (NYSE:HUM) Price Target Raised to $300.00 at Cantor Fitzgerald

Humana (NYSE:HUM) had its price objective boosted by analysts at Cantor Fitzgerald from $264.00 to $300.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the insurance provider’s stock. Cantor Fitzgerald’s price objective indicates a potential downside of 23.66% from the stock’s previous close.

HUM has been the subject of several other reports. Leerink Partners upped their target price on shares of Humana from $185.00 to $255.00 and gave the company a “market perform” rating in a research note on Thursday, April 30th. Wells Fargo & Company lowered shares of Humana from a “cautious” rating to a “reduce” rating in a report on Wednesday, May 20th. Morgan Stanley boosted their price objective on shares of Humana from $217.00 to $249.00 and gave the stock an “underweight” rating in a report on Thursday, June 4th. Deutsche Bank Aktiengesellschaft downgraded Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, May 20th. Finally, Evercore lifted their target price on Humana from $250.00 to $370.00 in a research report on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $294.65.

Humana Stock Performance

Humana stock opened at $393.00 on Tuesday. The stock’s 50 day moving average price is $321.87 and its 200 day moving average price is $250.40. The firm has a market capitalization of $47.18 billion, a PE ratio of 42.03, a price-to-earnings-growth ratio of 2.26 and a beta of 0.71. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.77 and a current ratio of 1.77. Humana has a one year low of $163.11 and a one year high of $415.00.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.97 by $0.34. Humana had a net margin of 0.82% and a return on equity of 10.45%. The company had revenue of $39.65 billion during the quarter, compared to the consensus estimate of $39.37 billion. During the same quarter last year, the company earned $11.58 earnings per share. Humana’s revenue for the quarter was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, sell-side analysts expect that Humana will post 9.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Humana

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Montag A & Associates Inc. lifted its position in shares of Humana by 1,880.0% during the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after purchasing an additional 94 shares during the last quarter. CoreCap Advisors LLC grew its stake in Humana by 54.4% in the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 37 shares in the last quarter. Fideuram Asset Management Ireland dac bought a new stake in Humana in the fourth quarter valued at about $27,000. Reflection Asset Management bought a new stake in Humana in the fourth quarter valued at about $29,000. Finally, Rosenberg Matthew Hamilton raised its stake in Humana by 136.0% during the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after buying an additional 68 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.